Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc., (HKG: 2696), a biopharmaceutical company based in China, has received approval...
Amgen’s Tezspire Shows Promise in Phase IIa COPD Trial, Reduces Exacerbations
Amgen (NASDAQ: AMGN), a multinational biopharmaceutical company, has this week announced results from a Phase...
Sichuan Biokin’s BL-B01D1 Earns Breakthrough Designation for Nasopharyngeal Carcinoma Treatment
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis
Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...
KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment
Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval...
AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...
J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact
Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...
China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare
Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...
Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...